P. van de Vaart

发表

Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy

M. Hoogeman, N. C. van der Voort van Zyp, J. Nuyttens, 2020, Acta oncologica.

Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab.

J. Aerts, E. Dieleman, M. Verheij, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Oral platinum analogue JM216, a radiosensitizer in oxic murine cells.

A. Begg, I. Hofland, P. van de Vaart, 1997, International journal of radiation biology.

Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer.

H. Bartelink, J. Benraadt, D. González González, 1996, European journal of cancer.

Interobserver variability in the delineation of the primary lung cancer and lymph nodes on different four-dimensional computed tomography reconstructions.

M. V. van Herk, J. Theuws, J. Pomp, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy

E. Kouwenhoven, N. C. van der Voort van Zyp, C. G. Gadellaa-van Hooijdonk, 2022, Clinical and translational radiation oncology.

In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.

R. Rietbroek, F. A. Blommaert, P. van de Vaart, 1996, Carcinogenesis.

The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma.

M. Hoogeman, S. Senan, J. Nuyttens, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.

J. Beijnen, W. W. ten Bokkel Huinink, F. Zoetmulder, 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.

H. Bartelink, J. Beijnen, A. Begg, 1998, European journal of cancer.

Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973).

G. Giaccone, H. Bartelink, C. Koning, 2007, European journal of cancer.

Predicting high-grade esophagus toxicity after treating central lung tumors with stereotactic radiotherapy using a Normal Tissue Complication Probability model.

M. Hoogeman, N. C. van der Voort van Zyp, J. Nuyttens, 2019, International journal of radiation oncology, biology, physics.

Translational research offers individually tailored treatments for cancer patients.

H. Bartelink, A. Begg, L. Moonen, 2000, The cancer journal from Scientific American.

Can errors in reconstructing pre-chemotherapy target volumes contribute to the inferiority of sequential chemoradiation in stage III non-small cell lung cancer (NSCLC)?

P. Voet, S. Senan, F. Lagerwaard, 2002, Lung cancer.

Verification measurements and clinical evaluation of the iPlan RT Monte Carlo dose algorithm for 6 MV photon energy

J. V. van Santvoort, R. Wiggenraad, A. Petoukhova, 2010, Physics in medicine and biology.

DNA‐adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy

H. Bartelink, D. de Jong, A. Begg, 2000, International journal of cancer.